The renin-angiotensin aldosterone system and osteoporosis: findings from the Women's Health Initiative.
Laura D CarboneS VasanR L PrenticeG HarshfieldB HaringJ A CauleyK C JohnsonPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2019)
In postmenopausal women, use of RAAS inhibitors, including ACE inhibitors and ARBs, is associated with an increased risk for fracture among new users of these medications in the first 3 years of use. However, long-term use (> 3 years) is associated with a reduced risk. Consideration for fracture risk may be part of the decision-making process for initiation of these medications for other disease states.